Well differentiated thyroid carcinoma is associated with human lymphocyte antigen D-related 11 in Eastern Hungarians: A case of changing circumstances

Cancer

Volumn 104, Issue 8, 2005, Pages 1603-1608

  Juhasz, Ferenz ^a   Kozma, Laszlo ^b   Stenszky, Valeria ^b   Gyory, Ferenc ^a   Luckas, Geza ^a   Farid, Nadir R ^c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c Osancor Biotech Inc   (United Kingdom)

Author keywords

Crystal structure; Human lymphocyte antigen D related 11; Immunomodulation; Lymphocytic infiltration; Metastases; Microcarcinoma; Radiation fall out; Well differentiated thyroid carcinoma

Indexed keywords

HLA D ANTIGEN; HLA DR1 ANTIGEN; HLA DR11 ANTIGEN;

ADULT; ARTICLE; ENVIRONMENTAL FACTOR; FEMALE; GENETIC SUSCEPTIBILITY; HLA TYPING; HUMAN; HUNGARY; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; THYROID CARCINOMA; TUMOR VOLUME;

ADENOCARCINOMA, FOLLICULAR; ADULT; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; FEMALE; GENES, MHC CLASS II; HLA-DR ANTIGENS; HLA-DR1 ANTIGEN; HUMANS; HUNGARY; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; THYROID NEOPLASMS;

EID: 26444496442     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21382     Document Type: Article

References (47)

1. Yu EY, Hahn WC. The origins of Cancer. In: Farid NR, editor. Molecular basis of thyroid cancer. Boston: Kluwer Academic Press, 2004:1-22.
2. Shi Y, Zou M. Matrix metalloproteases in thyroid cancer. In: Farid NR, editor. Molecular basis of thyroid cancer. Boston: Huwer Academic Press, 2004:179-190.
3. Blattman JN, Greenberg PD. Cancer Immunotherapy: a treatment for the masses. Science. 2004;305:200-205.
4. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360.
5. Puskas LG, Juhasz F, Zarva A, Hackler L Jr., Farid NR. Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors. Mol Cell Biol. In press.
6. Juhasz F, Boros P, Szegedi G, et al. Immunogenetic and immunologic studies of differentiated thyroid cancer. Cancer. 1989;63:1318-1326.
7. Juhasz F, Balazs G, Kozma L, Kraszits E, Stenszky V, Farid NR. Interaction of IgG heavy-chain allotypes (Gm) and HLA in conferring susceptibility to thyroid carcinoma Clin Endocrinol (Oxford). 1986;25:17-21.
8. Shi Y, Parhar RS, Zou M, et al. Gene therapy of anaplastic carcinoma with a single chain interleukin 12 fusion protein. Hum Gene Ther. 2004;14:1741-1751.
9. Farid NR. Are the immune responses to endocrine autoantigens genetically restricted? Autoimmunity. 1989;3:47-55.
10. van der Bruggen P, Zhang Y, Sroobant V, et al. Tumor-specific shared antigenic peptides recognized by human T cell. Immunol Rev. 2002;188:51-64.
11. Panza N, Del Vecchio L, Maio M, et al. Strong association between an HLA-DR antigen and thyroid carcinoma. Tissue Antigens. 1982;20:155-158.
12. Sridama V, Hara Y, Fauchet R, DeGroot LJ. Association of differentiated thyroid carcinoma with HLA-DR7. Cancer. 1985;56:1086-1088.
13. Juhasz F, Balazs G, Stenszky V, Kozma L, Farid NR. The relation of susceptibility to and biologic behavior of thyroid epithelial cell cancer to HLA-DR1. Cancer. 1986;58:52-54.
14. Larsen B, Thompson C, Kwan A, Farid NR. Lack of association of HLA with thyroid cancer. An effect of iodine sufficiency and safe environment? Tissue Antigens. 1986;28:298-300.
15. Dralle H, Robin-Winn M, Reilmann L, Laue A, Torok M. [HLA and thyroid cancer]. Klin Wochenschr. 1986;64:522-525.
16. Weissel M, Kainz H, Hoefer R, Mayr WR. HLA-DR and differentiated thyroid cancer. Lack of association with the non-medullary types and possible association with the medullary type. Cancer. 1988;62:2486-2488.
17. Ahuja S, Hoppe I, von Keyserlingk H, Ernst H. HLA and thyroid carcinoma. Exp Clin Endocrinol. 1992;99:134-136.
18. Rigopoulou D, Martinez-Laso J, Martinez-Tello F, et al. Both Class I and Class II HLA antigens are thyroid cancer susceptibility factors. Tissue Antigens. 1994;43:281-285.
19. Rios A, Rodriguez JM, Moya MR, et al. Frequency of HLA-C alleles in differentiated thyroid carcinoma in southeastern Spain. Cancer. 2004;100:264-269.
20. Sobin LH, Wittekind C, editors. TNM classification of malignant tumours, 5th ed. New York: John Wiley & Sons, 1997:52-56.
21. McLachlan GJ. Discriminant analysis and statistical pattern recognition. Hoboken, NJ: John Wiley & Sons, Inc, 2005.
22. Payami H, Joe S, Farid NR, et al. Relative predispositional effects (RPEs) of marker alleles with disease: HLA-DR alleles and Graves' disease. Am J Hum Genet. 1989;45:541-546.
23. Asa SL. The pathology of thyroid cancer. In: Farid NR, editor. Molecular basis of thyroid cancer. Boston: Kluwer Academic Press, 2004:23-67.
24. Lio D, Candore G, Colombo A, et al. A genetically determined high setting of TNF-alpha influences immunologic parameters of HLA-B8,DR3 positive subjects: implications for autoimmunity. Hum Immunol. 2001;62:705-713.
25. Wong AM, Allcock RJ, Cheong KY, Christiansen FT, Price P. Alleles of the proximal promoter of BAT1, a putative anti-inflammatory gene adjacent to the TNF cluster, reduce transcription on a disease-associated MHC haplotypes. Genes Cells. 2003;8:403-412.
26. Lee JE, Abdalla J, Porter GA, et al. Presence of the human leukocyte antigen Class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol. 2002;9:587-593.
27. Farid NR, Shi Y, Zou M. Molecular basis of thyroid cancer. Endocrine Rev. 1994;15:202-232.
28. Kroll TG. Molecular events in follicular thyroid tumors. In: Farid NR, editor. Molecular basis of thyroid cancer. Boston: Kluwer Academic Press, 2004:85-106.
29. Hwang ES, Kim DW, Song JH, et al. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary carcinoma) oncogenic tyrosine kinase. Mol Endocrinol. 2004;18:2672-2684.
30. Scarpino S, Stoppacciaro A, Ballerini F, et al. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am J Pathol. 2000;156:831-837.
31. Zeki K, Tanaka Y, Morimoto I, et al. Induction of expression of MHC-Class-II antigen on human thyroid carcinoma by wild-type p53. Int J Cancer. 1998;75:391-395.
32. Lahat N, Sobel E, Kraiem Z. Control of HLA-DR antigen expression by gamma-interferon: separate signal transduction mechanisms in malignant and nonmalignant human thyroid cells. Cancer Res. 1993;53:3943-3947.
33. Lahat N, Rahat MA, Sadeh O, Kinarty A, Kraiem Z. Regulation of HLA-DR and costimulatory B7 molecules in human thyroid carcinoma cells: differential binding of transcription factors to the HLA-DR alpha promoter. Thyroid. 1998;8:361-369.
34. Raphael SL, Asa SL. HLA-D antigen expression and Langerhans cell infiltrates in thyroid tumors. Endocrine Pathol. 1995;6:197-206.
35. Marx J. Inflammation and cancer: the link grows stronger. Science. 2004;306:966-968.
36. Powell DJ Jr., Eisenlohr LC, Rosthein JL. A thyroid tumor-specific antigen formed by the fusion of two self antigen. J Immunol. 2003;170:861-869.
37. Gedde-Dahl T 3rd, Sprunkland D, Eriksen JA, Thorsby E, Gaudernack G. Memory T cells of a patient which recognize peptides derived from mutated p21 ras (Gln→Leu61). Int Immunol. 1992;4:1331-1337.
38. Gyory F, Balazs G, Nagy EV, et al. Differentiated thyroid cancer and outcome in iodine deficiency. Eur J Surg Oncol. 2004;30:325-331.
39. Bachrati CZ, Pocsai G, Rasko I. RET/PTC fusion gene products in patients suffering from thyroid carcinomas. Laryngoscope. 1999;107:1011-1015.
40. Caudill CM, Zhu Z, Ciampi R, Stringer JR, Nikiforov YE. Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to γ-radiation: a model of carcinogenic chromosomal rearrangement induced by ionising radiation. J Clin Endocrinol Metab. 2005;90:2364-2369.
41. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray structure of HLA-DR4 (DRA-*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity. 1997;7:473-481.
42. Zavala-Ruiz Z, Sundberg EJ, Stone JD, et al. Exploration of the P6/P7 region of the peptide-binding site of the human Class II major histocompatability complex protein HLA-DR1. J Biol Chem. 2003;278:44904-44912.
43. Hammer J, Beleunis C, Bolin D, et al. High-affinity binding of short peptides to major histocompatability complex Class II molecules by anchor combinations. Proc Natl Acad Sci USA. 1994;91:4456-4460.
44. Moretta L, Moretta A. Killer immunoglobulin-like receptors. Curr Opin Immunol. 2004;16:626-633.
45. Gaudieri S, Nolan D, McKinnon E, Witt CS, Mallal S, Christiansen FT. Associations between KIR epitope combinations expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responses. Mol Immunol. 2005;42:557-560.
46. Spaggiari GM, Contini P, Dondero A, et al. Soluble HLA Class I induces NK cell apoptosis upon the engagement of killer-activating HLA Class I receptors through FasL-Fas interaction. Blood. 2002;100:4098-4107.
47. Vanherghhen B, Andersson, K, Carlin LM, et al. Human and inhibitory natural killer cell receptors transfer from natural killer cells to target cells Proc Natl Acad Sci USA. 20004;101:16873-16878.